Welcome to our dedicated page for Ardelyx news (Ticker: ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx stock.
Ardelyx, Inc. (Nasdaq: ARDX) is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that address significant unmet medical needs. The company's mission is to enhance the treatment of renal and gastrointestinal diseases through its proprietary drug discovery and design platform.
One of Ardelyx's lead products is tenapanor, which has been developed to reduce the absorption of dietary sodium and phosphorus. It is being investigated for multiple conditions, including hyperphosphatemia in patients with end-stage renal disease on dialysis and irritable bowel syndrome with constipation (IBS-C). The company has made significant strides in these areas, recently gaining FDA approval for tenapanor under the brand names IBSRELA® and XPHOZAH®. IBSRELA is targeted at treating IBS-C, while XPHOZAH is aimed at controlling serum phosphorus levels in patients with chronic kidney disease on dialysis.
Ardelyx has also forged strategic partnerships to extend the reach of its therapies globally. This includes collaborations with Kyowa Kirin in Japan, Fosun Pharma in China, and Knight Therapeutics in Canada. Notably, Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan, while a New Drug Application for the same indication is under review in China.
In its latest financial update, Ardelyx reported strong revenue growth for IBSRELA, achieving approximately $80 million in net product sales revenue for its first full year of commercialization. The company anticipates even higher sales in 2024, projecting revenues between $140 million and $150 million. Additionally, XPHOZAH, which launched in November 2023, recorded $2.5 million in net product sales revenue in its first quarter. To support these products, Ardelyx is investing in expanding its sales team and digital capabilities, as well as enhancing its patient services through the ArdelyxAssist™ program.
As of December 31, 2023, Ardelyx maintained a strong cash position with approximately $184 million in cash, cash equivalents, and short-term investments. The company’s financial stability and continuous investment in its robust R&D pipeline underscore its commitment to advancing the standard of care for patients with renal and gastrointestinal diseases.
Ardelyx continues to engage with the medical community and investors through various platforms, including regular webcasts and conferences. The company remains focused on executing its commercial strategy, expanding market penetration, and exploring new avenues for growth through internal development and external partnerships.
Ardelyx, Inc. (Nasdaq: ARDX) announced that CEO Mike Raab will participate in a virtual fireside chat at the 2022 Wedbush PacGrow Healthcare Conference. The chat is scheduled for August 9, 2022, at 4:40 p.m. ET. Interested parties can access the live webcast through the Investor section of the Ardelyx website, with a replay available for 30 days post-conference. Ardelyx focuses on developing innovative medicines to address significant medical needs, including their approved product IBSRELA and products in development for conditions like CKD and hyperkalemia.
Ardelyx, Inc. (Nasdaq: ARDX) will hold a conference call on August 4, 2022, at 4:30 p.m. Eastern Time to discuss its second quarter 2022 financial results and provide a business overview. The call will be accessible via telephone registration through an online form, and a live audio webcast will also be available on Ardelyx's website. Ardelyx focuses on developing innovative medicines, including its approved product IBSRELA® and the pipeline candidates XPHOZAH® and RDX013, targeting significant medical needs.
On June 28, 2022, Ardelyx, Inc. (Nasdaq: ARDX) announced the granting of stock options and Restricted Stock Units (RSUs) to six new non-executive employees as employment inducements. The options total 332,483 shares, priced at $0.57, the closing stock price on the grant date, while RSUs amount to 83,375 shares. Both stock options and RSUs vest over four years. Ardelyx focuses on developing innovative medicines, including IBSRELA® and XPHOZAH®, with partnerships in Japan, China, and Canada.
Ardelyx, Inc. announced it may receive up to $20 million from HealthCare Royalty Partners for future royalties from its collaboration with Kyowa Kirin on tenapanor for hyperphosphatemia. This financing validates the potential of tenapanor in Japan. Ardelyx will get $10 million upfront, $5 million post-regulatory approval, and another $5 million upon meeting sales targets. Overall, Ardelyx could gain $85 million in non-dilutive capital from Kyowa Kirin's development progress, despite reduced royalty rates from high teens to mid-single digits during the agreement period.
Ardelyx, Inc. (Nasdaq: ARDX) announced that the FDA has scheduled a meeting of the Cardiovascular and Renal Drugs Advisory Committee on November 16, 2022. This meeting will review the New Drug Application (NDA) for XPHOZAH, which aims to control serum phosphorus in adult patients with chronic kidney disease on dialysis. The FDA highlighted the need for expert input regarding the phosphate-lowering effect observed in Ardelyx's Phase 3 trials. A formal response to Ardelyx's appeal is expected within 30 days post-meeting.
Ardelyx, Inc. (Nasdaq: ARDX) has announced that CEO Mike Raab will participate in a fireside chat at the Jefferies Healthcare Conference on June 10, 2022, at 8:30 a.m. ET in New York City. The event aims to showcase Ardelyx's innovative biopharmaceutical developments, including its approved product IBSRELA and the candidate XPHOZAH, which targets serum phosphorus control in CKD patients. A live webcast of the presentation will be available on the company’s investor website, with a replay accessible for 30 days.
On May 24, 2022, Ardelyx presented new data on IBSRELA from Phase 3 trials T3MPO-1 and T3MPO-2 at the Digestive Disease Week Conference. The presentations highlighted IBSRELA's safety and efficacy in adults with irritable bowel syndrome with constipation (IBS-C). Results showed significant symptom relief, treatment satisfaction, and quality of life improvements compared to placebo. IBSRELA is FDA-approved for treating IBS-C and offers a novel mechanism for addressing this condition, impacting millions in the US.
Ardelyx, Inc. (Nasdaq: ARDX) announced that new data highlighting the efficacy and safety of IBSRELA will be presented at the 2022 Digestive Disease Week Conference from May 21-24, 2022. Key presentations include findings on long-term treatment with Tenapanor for IBS-C and its impact on patient satisfaction and early onset of action. Additionally, Ardelyx is sponsoring a Product Theater featuring expert discussions on IBSRELA’s innovative treatment approach and trial efficacy data. Safety warnings for pediatric use are emphasized due to dehydration risks.
Ardelyx, Inc. (Nasdaq: ARDX) announced that new data showcasing the efficacy and safety of IBSRELA (tenapanor) will be presented at the 2022 Digestive Disease Week Conference (DDW) from May 21-24 in San Diego, California. The presentations include three posters focusing on long-term treatment benefits and patient quality of life. Additionally, Ardelyx will sponsor a Product Theater on May 23, discussing IBSRELA's innovative approach in treating Irritable Bowel Syndrome with Constipation (IBS-C). IBSRELA is indicated for adults and has demonstrated promise in improving symptoms.
On May 16, 2022, Ardelyx, Inc. (NASDAQ: ARDX) announced the granting of stock options and Restricted Stock Units (RSUs) to new non-executive employees as part of their employment inducements. A total of 26,953 stock options and 29,250 RSUs were granted, with each stock option priced at $0.72, the company's closing stock price on the grant date. The options vest over four years, while RSUs follow a similar vesting schedule. Ardelyx continues its mission to develop innovative medicines, with ongoing programs targeting significant medical needs.
FAQ
What is the current stock price of Ardelyx (ARDX)?
What is the market cap of Ardelyx (ARDX)?
What is Ardelyx, Inc. focused on?
What are the main products of Ardelyx?
How has Ardelyx performed financially in recent years?
What strategic partnerships does Ardelyx have?
What is tenapanor used for?
What is the ArdelyxAssist™ program?
What is the financial status of Ardelyx?
Where can investors find more information about Ardelyx?
What recent achievements has Ardelyx made?
What future plans does Ardelyx have?
